651 related articles for article (PubMed ID: 23371904)
1. Progress in the reprogramming of somatic cells.
Ma T; Xie M; Laurent T; Ding S
Circ Res; 2013 Feb; 112(3):562-74. PubMed ID: 23371904
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological Reprogramming of Somatic Cells for Regenerative Medicine.
Xie M; Tang S; Li K; Ding S
Acc Chem Res; 2017 May; 50(5):1202-1211. PubMed ID: 28453285
[TBL] [Abstract][Full Text] [Related]
3. Chemically Induced Reprogramming of Somatic Cells to Pluripotent Stem Cells and Neural Cells.
Biswas D; Jiang P
Int J Mol Sci; 2016 Feb; 17(2):226. PubMed ID: 26861316
[TBL] [Abstract][Full Text] [Related]
4. Effect of small molecules on cell reprogramming.
Baranek M; Belter A; Naskręt-Barciszewska MZ; Stobiecki M; Markiewicz WT; Barciszewski J
Mol Biosyst; 2017 Jan; 13(2):277-313. PubMed ID: 27918060
[TBL] [Abstract][Full Text] [Related]
5. Small molecules for reprogramming and transdifferentiation.
Qin H; Zhao A; Fu X
Cell Mol Life Sci; 2017 Oct; 74(19):3553-3575. PubMed ID: 28698932
[TBL] [Abstract][Full Text] [Related]
6. RNA-based tools for nuclear reprogramming and lineage-conversion: towards clinical applications.
Bernal JA
J Cardiovasc Transl Res; 2013 Dec; 6(6):956-68. PubMed ID: 23852582
[TBL] [Abstract][Full Text] [Related]
7. Reprogram or reboot: small molecule approaches for the production of induced pluripotent stem cells and direct cell reprogramming.
Jung DW; Kim WH; Williams DR
ACS Chem Biol; 2014 Jan; 9(1):80-95. PubMed ID: 24245936
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic Control of Reprogramming and Transdifferentiation by Histone Modifications.
Qin H; Zhao A; Zhang C; Fu X
Stem Cell Rev Rep; 2016 Dec; 12(6):708-720. PubMed ID: 27623868
[TBL] [Abstract][Full Text] [Related]
9. Cellular Reprogramming Using Protein and Cell-Penetrating Peptides.
Seo BJ; Hong YJ; Do JT
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28273812
[TBL] [Abstract][Full Text] [Related]
10. Induced pluripotent stem cells: fundamentals and applications of the reprogramming process and its ramifications on regenerative medicine.
Walia B; Satija N; Tripathi RP; Gangenahalli GU
Stem Cell Rev Rep; 2012 Mar; 8(1):100-15. PubMed ID: 21671061
[TBL] [Abstract][Full Text] [Related]
11. Chemical reprogramming and transdifferentiation.
Xie X; Fu Y; Liu J
Curr Opin Genet Dev; 2017 Oct; 46():104-113. PubMed ID: 28755566
[TBL] [Abstract][Full Text] [Related]
12. Understanding the roadmaps to induced pluripotency.
Liu K; Song Y; Yu H; Zhao T
Cell Death Dis; 2014 May; 5(5):e1232. PubMed ID: 24832604
[TBL] [Abstract][Full Text] [Related]
13. Cellular reprogramming: a small molecule perspective.
Nie B; Wang H; Laurent T; Ding S
Curr Opin Cell Biol; 2012 Dec; 24(6):784-92. PubMed ID: 22959962
[TBL] [Abstract][Full Text] [Related]
14. Transient acquisition of pluripotency during somatic cell transdifferentiation with iPSC reprogramming factors.
Maza I; Caspi I; Zviran A; Chomsky E; Rais Y; Viukov S; Geula S; Buenrostro JD; Weinberger L; Krupalnik V; Hanna S; Zerbib M; Dutton JR; Greenleaf WJ; Massarwa R; Novershtern N; Hanna JH
Nat Biotechnol; 2015 Jul; 33(7):769-74. PubMed ID: 26098448
[TBL] [Abstract][Full Text] [Related]
15. Fusion of Reprogramming Factors Alters the Trajectory of Somatic Lineage Conversion.
Velychko S; Kang K; Kim SM; Kwak TH; Kim KP; Park C; Hong K; Chung C; Hyun JK; MacCarthy CM; Wu G; Schöler HR; Han DW
Cell Rep; 2019 Apr; 27(1):30-39.e4. PubMed ID: 30943410
[TBL] [Abstract][Full Text] [Related]
16. Somatic cell reprogramming as a tool for neurodegenerative diseases.
Ebrahimi A; Keske E; Mehdipour A; Ebrahimi-Kalan A; Ghorbani M
Biomed Pharmacother; 2019 Apr; 112():108663. PubMed ID: 30970509
[TBL] [Abstract][Full Text] [Related]
17. Induced pluripotency and direct reprogramming: a new window for treatment of neurodegenerative diseases.
Li R; Bai Y; Liu T; Wang X; Wu Q
Protein Cell; 2013 Jun; 4(6):415-24. PubMed ID: 23686735
[TBL] [Abstract][Full Text] [Related]
18. Engineering cell fate: Spotlight on cell-activation and signaling-directed lineage conversion.
Ebrahimi B
Tissue Cell; 2016 Oct; 48(5):475-87. PubMed ID: 27514850
[TBL] [Abstract][Full Text] [Related]
19. Residual expression of reprogramming factors affects the transcriptional program and epigenetic signatures of induced pluripotent stem cells.
Sommer CA; Christodoulou C; Gianotti-Sommer A; Shen SS; Sailaja BS; Hezroni H; Spira A; Meshorer E; Kotton DN; Mostoslavsky G
PLoS One; 2012; 7(12):e51711. PubMed ID: 23272148
[TBL] [Abstract][Full Text] [Related]
20. NKX3-1 is required for induced pluripotent stem cell reprogramming and can replace OCT4 in mouse and human iPSC induction.
Mai T; Markov GJ; Brady JJ; Palla A; Zeng H; Sebastiano V; Blau HM
Nat Cell Biol; 2018 Aug; 20(8):900-908. PubMed ID: 30013107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
